HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmac

BlackRock Inc. bought a new stake in Arcus Biosciences, Inc. (NYSE: RCUS) during the second quarter,

NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biop

Arcus Biosciences NYSE: RCUS outlined plans to expand development of its casdatifan cancer program a

Wells Fargo analyst Eva Fortea Verdejo maintains Arcus Biosciences (NYSE:RCUS) with a Equal-Weigh

Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and rai

Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $0.72 per share versus the Zacks Co

Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.72) per share which beat the analyst

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biop

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is i

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biop

Summit announces updated HARMONi overall survival data and partners with Arcus to test ivonescimab i

This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational c

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global bio

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on d

HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, gl

HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)---- $SMMT--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmac

HC Wainwright raised its price forecast for Arcus Biosciences Inc. (NASDAQ:RCUS), citing the aggress

HC Wainwright lifted Arcus Biosciences' price target, citing broader revenue potential for casda

HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences (NYSE:RCUS) with a Buy a

This sale was executed under a Rule 10b5-1 plan following a 203% one-year surge.

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biop

This is the first study to comprehensively interconnect clinical outcomes from patients receiving a

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global bio

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biop

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on d

Truist Securities analyst Supawat Thongthip assumes Arcus Biosciences (NYSE:RCUS) with a Buy rati

Morgan Stanley analyst Terence Flynn maintains Arcus Biosciences (NYSE:RCUS) with a Equal-Weight

Goldman Sachs analyst Richard Law maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises

Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.02) per share which missed the analys

Arcus Biosciences halts STAR-121 lung cancer trial after futility review while Gilead Science declin

Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and rai

Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises

Leerink Partners analyst Geoffrey Porges maintains Arcus Biosciences (NYSE:RCUS) with a Outperfor

HC Wainwright & Co. analyst Emily Bodnar reiterates Arcus Biosciences (NYSE:RCUS) with a Buy

Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.89) per share which beat the analyst

Wells Fargo analyst Eva Fortea Verdejo downgrades Arcus Biosciences (NYSE:RCUS) from Overweight t

Goldman Sachs analyst Richard Law upgrades Arcus Biosciences (NYSE:RCUS) from Neutral to Buy and

Morgan Stanley analyst Terence Flynn downgrades Arcus Biosciences (NYSE:RCUS) from Overweight to

Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan,

HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences (NYSE:RCUS) with a Buy a